Coagulation Factor IX, Human Plasma

MFCD00163303

Native coagulation factor IX from human plasma. Sold on the basis of plasma equivalent units. 100 plasma equivalent units are equal to 500 µg of Factor IX. In vivo, activation of Factor IX to IXa occurs via either the tissue factor/Factor VIIa complex (the extrinsic pathway), or Factor XIa (the intrinsic pathway). Activated Factor IXa, in a complex with Factor VIIa, can then convert Factor X to Xa, the catalytic component of the prothrombinase complex.
Native coagulation factor IX from human plasma. Sold on the basis of plasma equivalent units. 100 plasma equivalent units are equal to 500 µg of Factor IX. In vivo, activation of Factor IX to IXa occurs via either the tissue factor/Factor VIIa complex (the extrinsic pathway), or Factor XIa (the intrinsic pathway). Activated Factor IXa, in a complex with Factor VIIIa, can then convert Factor X to Xa, the catalytic component of the prothrombinase complex.

Toxicity: Standard Handling (A)

In 100 mM NaCl, 20 mM Tris-HCl, 1 mM benzamidine, pH 7.5.

Prepared from plasma that has been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.

Following initial thaw, aliquot and freeze (-70°C).

Clotting activity is determined by comparison to a standard curve produced using normal pooled human plasma

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

200

≥95% (SDS-PAGE)

liquid

≥150 units/mg protein (clotting assay)

Calbiochem^®

OK to freeze
avoid repeated freeze/thaw cycles

wet ice

−70℃

100 u in Plastic ampoule
Please refer to vial label for lot-specific concentration.

12 - Non Combustible Liquids

WGK 1